Phase 3Not yet recruiting
A Phase 3 Trial in Advanced Epithelioid Mesothelioma (sTEADfast)
A Phase 3, Randomized, Open-label Trial Comparing VT3989 Versus Gemcitabine or Vinorelbine in Participants With Advanced Epithelioid Mesothelioma, Who Previously Received Platinum-Based Systemic Chemotherapy and Immunotherapy
- Sponsor
- Vivace Therapeutics, Inc (Industry)
- Enrollment
- 350 planned
- Conditions
- Pleural Mesothelioma; Mesothelioma
- Interventions
- VT3989; gemcitabine; Vinorelbine
- Ages
- adults, older adults
- Registry
- NCT07824986
Full record on ClinicalTrials.gov
From the registry
This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior platinum-based systemic chemotherapy and immunotherapy.
Primary outcomes
- Overall Survival (OS)
History
Study completion expected
Primary completion expected
Expected to start
Registered